Alto Neuroscience (NYSE:ANRO) Upgraded at Wall Street Zen

Alto Neuroscience (NYSE:ANRO) was upgraded by research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Several other research analysts also recently weighed in on the company. Bank of America initiated coverage on Alto Neuroscience in a research note on Tuesday, May 5th. They set a “buy” rating and a $35.00 target price for the company. Wedbush upped their price objective on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Thursday, May 14th. HC Wainwright reaffirmed a “buy” rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. Weiss Ratings upgraded shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 1st. Finally, JonesTrading cut their target price on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research note on Thursday, April 2nd. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.25.

Alto Neuroscience Price Performance

NYSE:ANRO opened at $27.54 on Friday. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 52 week low of $2.72 and a 52 week high of $28.85. The stock’s 50-day moving average price is $23.17 and its 200-day moving average price is $21.18. The stock has a market capitalization of $966.52 million, a PE ratio of -11.38 and a beta of 1.04.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, equities analysts expect that Alto Neuroscience will post -3.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Alto Neuroscience

A number of large investors have recently made changes to their positions in ANRO. Commodore Capital LP lifted its position in Alto Neuroscience by 49.4% during the first quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock worth $61,217,000 after buying an additional 900,000 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Alto Neuroscience by 161.6% in the 4th quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares during the last quarter. Perceptive Advisors LLC raised its holdings in shares of Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after acquiring an additional 225,500 shares during the period. Armistice Capital LLC boosted its position in shares of Alto Neuroscience by 0.7% during the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after acquiring an additional 12,000 shares during the last quarter. Finally, Spruce Street Capital LP grew its holdings in shares of Alto Neuroscience by 494.7% in the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after purchasing an additional 1,102,366 shares during the period.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.